Stifel Maintains Buy on Summit Therapeutics, Raises Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Bradley Canino maintains a Buy rating on Summit Therapeutics and raises the price target from $14 to $25.
September 09, 2024 | 2:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stifel analyst Bradley Canino has increased the price target for Summit Therapeutics from $14 to $25 while maintaining a Buy rating. This suggests a positive outlook for the company's stock.
The increase in price target from $14 to $25 by a reputable analyst indicates a strong positive sentiment towards Summit Therapeutics. This is likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100